Find Information on a:
| Specific Medicine or Treatment |
| Type of Medicine or Treatment |
| Condition or Medical Procedure |
| Lab Test Procedure |
| Management Issue |
View all Postings for:
| Health Care Providers |
| Patients & Caregivers |
Search ClotCare
|
We comply with the HONcode standard for trustworthy health information: verify here. |
ATryn Available for Patients with Hereditary Antithrombin Deficiency, a Rare Blood Clotting Disorder
Press Release from Lundbeck, Inc.
May, 2009
Lundbeck Inc. offers recombinant antithrombin treatment option
May 6, 2009 - Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark (LUN: Copenhagen Stock Exchange), announced today that ATryn® (Antithrombin [Recombinant]) is now available in the United States. In February 2009, the U.S. Food and Drug Administration (FDA) granted marketing approval of ATryn, developed through recombinant technology, for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary antithrombin deficiency (HD AT), a rare and potentially fatal blood clotting disorder. ATryn is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients. The product is marketed in the U.S. by Lundbeck Inc. and manufactured by GTC Biotherapeutics, Inc. (NASDAQ: GTCB)....
Click here to download the complete press release from Lundbeck, Inc.
Terms, Conditions, & Privacy | Image Copyright Information
Send comments to webmaster@clotcare.org.
ClotCare is a charitable 501(c)(3) non-profit organization. Click here to donate.